Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

NCT04515836 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT04515836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04515836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
February 19, 2021
Completion date
April 15, 2028
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

homologous recombination deficiency, mesothelioma